Full Text View
Tabular View
No Study Results Posted
Related Studies
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
This study has been completed.
Study NCT00761449   Information provided by Nordic MDS Group

First Received on September 26, 2008.   Last Updated on April 26, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
MDS
AML
Additional conditions recognized in this trial
Monosomy
More general conditions related to this trial
Aneuploidy
Chromosome Aberrations
Pathologic Processes
Interventions listed in this trial
lenalidomide
Additional drug interventions recognized in this trial
Thalidomide
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Nordic MDS Group


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services